NanoViricides Inc. (NNVC)

[arvitar]

Once the board realized that Diwan's "cure-machine" can't be commercialized, they did have viable alternatives to paying Seymour and Diwan just for breathing and misleading the investing public. Those would include hiring a more qualified and capable CEO whose task would be to in-license more promising early-stage compounds from other companies or university labs.

With $20M currently in their bank account, those options are still available. Obviously that won't happen with the finger-puppet board.

I predict at least several future lawsuits against the board for their negligence in this regard.